OnaBoNT-A
ApprovedBiologic
IpsenOnaBoNT-A is one of 81 biologic programs targeting Cerebral Palsy. It is currently in Approved.
4
Indications
4
Total Trials
1
Active Trials
80
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
150 competitors in Overactive Bladder
#DrugCompanyPhaseTrials
1Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Botox
AbbViePhase 3
OnaBoNT-A
IpsenApproved
GSK1358820
GSKPhase 3
Tolterodine PR
PfizerPhase 3
Oxybutynin Chloride
Mylan Pharmaceuticals IncPhase 3
Vesicare
AstellasPhase 3
YM178
AstellasPhase 3
SPM 907
PfizerPhase 3
Standard Medication Therapy
QQing Yuan
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Overactive Bladder1 trial
Cerebral Palsy1 trial
Botulinum Toxin Injection for Sialorrhea in Cerebral Palsy
Completed·—··NCT06101160·61 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for OnaBoNT-A. EMBL-EBI & Wellcome Sanger Institute.
- [4]